SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Download PDF Copy

Mar 31 2010

Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company's lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.

SCY-635 is a novel cyclophilin inhibitor and represents a new pharmacological class of inhibitors of HCV replication. SCY-635 has shown strong single-agent antiviral activity in a Phase 1b clinical study and has also demonstrated promising antiviral activity when combined with a wide range of mechanistically diverse anti-HCV agents. SCYNEXIS expects to initiate a Phase 2 study for SCY-635 in the second quarter of 2010.

Source: SCYNEXIS

Posted in: Drug Trial News

Tags: Cell, Cyclosporine, Drug Discovery, Hepatitis, Hepatitis A, Hepatitis B, Hepatitis B Virus, Hepatitis C, Hepatitis D, Hepatitis E, Immunosuppression, Prophylaxis, Transplant, Virology, Virus

Comments (0)

Download PDF Copy

Suggested Reading

Extended liver preservation technique shows promise for daytime transplants

Extended liver preservation technique shows promise for daytime transplants

How did machine learning models perform in identifying hepatitis in patients with diabetes?

How did machine learning models perform in identifying hepatitis in patients with diabetes?

Study shows synergistic effects of genetic factors, binge drinking, and diabetes in alcohol-related cirrhosis

Study shows synergistic effects of genetic factors, binge drinking, and diabetes in alcohol-related cirrhosis

Paxlovid enhances treatment options for COVID-19 patients

Paxlovid enhances treatment options for COVID-19 patients

New optimized vaccine approach targets Hepatitis C virus variability

New optimized vaccine approach targets Hepatitis C virus variability

Study reveals intestinal helminth infection diminishes T cell response to COVID-19 mRNA vaccine

Study reveals intestinal helminth infection diminishes T cell response to COVID-19 mRNA vaccine

Elton John welcomes expansion of opt-out testing for HIV to 46 Accident & Emergency sites across England and calls on all political leaders to do more to end AIDS in a speech at Speaker's House

Elton John welcomes expansion of opt-out testing for HIV to 46 Accident & Emergency sites across England and calls on all political leaders to do more to end AIDS in a speech at Speaker's House

Machine learning model to determine associations between metabolic syndrome and lactation

Machine learning model to determine associations between metabolic syndrome and lactation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Exploring the global health challenge of hepatitis D